Engineering Microneedle Patches for Improved Penetration: Analysis, Skin Models and Factors Affecting Needle Insertion.
Makvandi P, Kirkby M, Hutton ARJ, Shabani M, Yiu CKY, Baghbantaraghdari Z, Jamaledin R, Carlotti M, Mazzolai B, Mattoli V, Donnelly RF. · 2021
Read Engineering Microneedle Patches for Improved Penetration: Analysis, Skin Models and Factors Affecting Needle Insertion. by Makvandi P, Kirkby M, Hutton ARJ, Shabani M, Yiu CKY, Baghbantaraghdari Z, Jamaledin R, Carlotti M, Mazzolai B, Mattoli V, Donnelly RF. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8006208.txt.
Introduction
Makvandi and co-authors review what decides whether microneedle patches pierce skin well. Microneedles deliver drugs through the skin, either into the skin layers or into the body at large. The route skips digestion and first-pass metabolism in the liver. But needles can break, bend, or fail to enter the skin at all.
The review weighs needle geometry, height, tip radius, and material strength. It also covers skin thickness and elasticity. The authors survey artificial and computational skin models used to simulate insertion. Mechanical tests that measure insertion force get close attention. Better insertion means less wasted drug and safer, more reliable patches.
Catalog record
| CREATOR | Makvandi P, Kirkby M, Hutton ARJ, Shabani M, Yiu CKY, Baghbantaraghdari Z, Jamaledin R, Carlotti M, Mazzolai B, Mattoli V, Donnelly RF. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 147 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Engineering Microneedle Patches for Improved Penetration: Analysis, Skin Models and Factors Affecting Needle Insertion By Pooyan Makvandi, Melissa Kirkby, Aaron R J Hutton, Majid Shabani, Cynthia K Y Yiu, Zahra Baghbantaraghdari, Rezvan Jamaledin, Marco Carlotti, Barbara Mazzolai, Virgilio Mattoli, Ryan F Donnelly Published in: Nano-Micro Letters DOI: 10.1007/s40820-021-00611-9 ABSTRACT Highlights - Factors affecting microneedle insertion into skin are reviewed. - The use of artificial and computational skin models for the simulation of needle insertion is summarized. - Skin structures and models, as well as mechanical analyses, used to determine transdermal microneedle ability to insert into skin are highlighted in the review. Keywords: Insertion responsive, Implantable microneedles, Skin indentation, Transdermal microneedles, Pain management INTRODUCTION Drug delivery using microneedles (MNs) through the skin is an attractive route of administration [1–3]. The major advantages of MN-mediated drug delivery are the ability to deliver drugs through a large surface area, administration feasibility [4–7], avoidance of first-pass metabolism and gastrointestinal degradation [8, 9]. Drug delivery via the skin is useful either for releasing the drug into the layers of skin at the site of administration (e.g., skin abnormalities treatment and vaccination) known as dermal delivery [10, 11], or by delivering the cargo systemically through the administration from the skin known as transdermal delivery (e.g., insulin therapy) [12, 13]. Apart from the many benefits provided by MNs, a number of challenges must be overcome to achieve a clinically acceptable drug delivery device. For instance, fracture or breakage of needles during or after patch administration may change the drug release profile, which may lead to premature drug release. This problem with needle fracture may be due to inadequate mechanical strength. Debris that remains in the skin may cause harm to the surrounding tissue [14, 15]. MNs can also bend or twist while inserting in the skin [16]. Consequently, the cargo can be liberated prematurely, which prohibits controlled drug release [17]. Furthermore, MNs often suffer from insufficient skin insertion. This occurs when MNs are not able to sufficiently puncture and penetrate into the skin, which may waste the drug formulated in the MN [14, 17, 18]. At their most fundamental level, MNs must show sufficient insertion into skin and therefore must demonstrate sufficient strength to penetrate without breaking or bending during application. Although such a task appears relatively simple upon first appearance, numerous factors are accountable for adequate MN insertion, such as geometry, needle height, thickness and tip radius, base diameter, needle density, and MN material [19]. This is in addition to factors such as skin thickness and elasticity, which are unrelated to the MNs themselves but will also have an effect on the efficiency of MN insertion [20, 21]. For the clinical acceptance of MNs, it is imperative that they can reliably insert into the skin without bending, buckling or fracturing. A wide range of MN designs exists within the literature in an attempt to optimize the insertion for clinical applications [22, 23]. The present review deals with the skin penetration of MN and the employed strategies to circumvent this hurdle. Herein, an introduction on pain signal and its management is discussed, as well as a comparison between pain caused by MNs and a traditional hypodermic needle. Thereafter, skin structure, its mechanical behavior, and skin resealing are discussed. In addition, mechanical tests, skin models, and penetration tests used to assess MN insertion before clinical practice are presented. Ultimately, emphasis is given to factors affecting insertion (such as geometry, material composition, and cross-linking of MNs), which is accompanied by modern progressions in developed strategies, pedestal-based platform, to name a few, to improve MNs’ skin insertion and to pave the way for future research. PAIN MANAGEMENT Broadly stated, there are four phases in the nociception of pain: (1) transduction, (2) transmission, (3) perception, and (4) modulation [24]. Pain detection is mediated by nociceptors which are present in the skin, deep tissues, and internal organs, with the skin a densely populated area containing different types of sensory afferents [25]. Transduction is the first process of nociception, which involves the conversion of a noxious stimulus into electrical signals in the peripheral terminals of nociceptor sensory fibers [24]. Nociceptors are essentially sensory receptors located at the free endings of first-order afferent neurons (Aδ and C fibers) in the pain pathway. The larger, fast-conducting lightly myelinated Aδ fibers are activated by mechanical and thermal stimuli, which are responsible for the initial sharp pain perceived at the time of injury. Conversely, the smaller, slow-conducting unmyelinated C fibers respond to chemical, mechanical, and thermal stimuli with a high activation threshold. Such fibers therefore are associated with a longer-lasting, diffusing pain [26]. These nociceptors detect noxious stimuli and turn the stimuli into electric signals, which are then sent to the central nervous system. Both the Aδ and C fibers have their cell bodies within the dorsal root ganglion, which allow rapid transmission of the stimulus from the periphery to the spinal cord. Transduction is followed by transmission, which includes the conduction of action potentials from the peripheral terminal along axons to the central terminal of nociceptors in the central nervous system [24]. First-order neurons carry the noxious information from the point of stimuli in the skin to the spinal cord via the dorsal root, where they synapse with the second-order neurons in the dorsal horn. The dorsal horn is divided into laminae (called Rexed laminae), whilst the C fibers terminate in lamina II and the Aδ fibers terminate in laminae I and V [27]. These second-order neurons then cross over to the other side of the spinal cord before ascending to the brain. There are two major pathways that carry nociceptive signals from the spinal cord to the brain, the spinothalamic and spinoreticular tracts, which are located in the anterolateral white matter of the spinal cord [24]. In the first pathway, second-order neurons ascend from the contralateral spinothalamic tract before terminating in the ventral posterolateral nuclei and central nuclei of the thalamus, where they synapse with third-order neurons, which play a major role for processing somatosensory information [27]. The third-order neuron then projects via the posterior limb of the internal capsule to terminate in the ipsilateral post-central gyrus (primary somatosensory cortex); this pathway is involved in the localization and intensity of the painful stimulus [28]. Simultaneously in the spinoreticular tract, fibers ascend the contralateral cord to the reticular formation of the brainstem before running up to the thalamus, hypothalamus and ultimately the cortex; this pathway is responsible for the emotional aspect of pain [27]. Hence, pain signals from the skin will terminate in the cortex to interpret the pain sensation. The perception of pain constitutes the third process of nociception. Modulation is the final process in nociception, which is an adaptive process involving both excitatory and inhibitory mechanisms, thereby altering the perception of pain [24]. Nociceptive signaling may be augmented by central mechanisms of hyperalgesia (exaggerated pain following noxious stimuli) or allodynia (pain from a typically harmless stimulus), and in contrary, nociceptive signaling may also be decreased by endogenous analgesia systems [29]. The basic diagram of pain transmission is presented in Fig. 1. [Figure: The basic route of pain transmission upon noxious stimuli. There are the four phases (transduction, transmission, perception, and modulation) in the nociception